公开(公告)号：WO2007056192A3

公开(公告)日：2007-07-05

申请号：PCT/US2006043050

申请日：2006-11-02

Applicant: BECKMAN COULTER INC ,  UNIV NORTHWESTERN ,  UNIV HEALTH NETWORK ,  UNIV CASE WESTERN RESERVE ,  ALLEGHENY SINGER RES INST ,  GOOLSBY CHARLES ,  SHANKEY VINCENT T ,  HEDLEY DAVID ,  JACOBBERGER JAMES ,  SHACKNEY STANLEY

Inventor： GOOLSBY CHARLES ,  SHANKEY VINCENT T ,  HEDLEY DAVID ,  JACOBBERGER JAMES ,  SHACKNEY STANLEY

IPC: G01N33/53 ,  G01N33/574

CPC classification number: G01N33/57426 ,  G01N33/5052 ,  G01N2800/52

Abstract: The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).

Abstract translation: 本发明涉及用于建立来源于疑似患有肿瘤性病症的个体的样品的复合标志物分布图的方法。 本发明的复合标志物概况允许鉴定预后和治疗相关的肿瘤病症亚组和预测个体的临床过程。 本发明的方法提供了用于为患有赘生性病症的个体选择治疗的工具，包括用于分配风险组的方法，预测复发风险增加的方法，预测发生继发性并发症的风险增加的方法，方法 为个体选择治疗的方法，确定个体治疗功效的方法以及确定个体预后的方法。 具体而言，本发明的方法公开了一种用于建立复合标志物分布图的方法，其可以用作预测指标以预测个体中瘤性病症的进程是侵略性的还是惰性的，由此帮助临床医生管理 患者并评估待使用的治疗方式。 在本文公开的具体实施方案中，本发明的方法涉及建立选自慢性淋巴细胞性白血病（CLL），急性骨髓性白血病（AML），慢性骨髓性白血病（CML）和 急性淋巴细胞白血病（ALL）。

公开(公告)号：WO2007098607A8

公开(公告)日：2016-10-27

申请号：PCT/CA2007000346

申请日：2007-03-05

Applicant: AMORFIX LIFE SCIENCES LTD ,  UNIV HEALTH NETWORK ,  CASHMAN NEIL R ,  CHAKRABARTTY AVIJIT ,  RAKHIT RISHI ,  OSTERMAN JOACHIM BERNHARD

Inventor： CASHMAN NEIL R ,  CHAKRABARTTY AVIJIT ,  RAKHIT RISHI ,  OSTERMAN JOACHIM BERNHARD

IPC: C12N15/53 ,  A61K31/7088 ,  A61K38/44 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  A61P25/28 ,  C07K16/40 ,  C12N5/12 ,  C12N9/02 ,  G01N33/573

CPC classification number: C07K16/40 ,  A01K2267/0312 ,  A01K2267/0318 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/0005 ,  A61K39/0007 ,  A61K48/005 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/575 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/0089 ,  G01N33/573 ,  G01N33/6896 ,  G01N2333/90283 ,  G01N2800/2828

Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention.

Abstract translation: 本发明提供了在需要治疗的受试者中治疗由错误折叠形式的超氧化物歧化酶（SOD）介导的医学病症，疾病或病症的方法。 所述方法任选包括向受试者施用包含药学上可接受的载体和选自（1）选择性结合SOD的错误折叠形式的外源性抗体或其片段的组合物，和/或（2）引起生产的免疫原 选择性结合SOD的错误折叠形式的内源性抗体，和/或（3）编码（1）或（2）的核酸序列。 在某些实施方案中，本发明提供了使用肌萎缩性疾病特异性表位治疗疾病如阿尔茨海默病，帕金森病或肌萎缩性侧索硬化的方法，以及包括这些表位的组合物。 本发明还提供结合单体或错折叠的SOD1，而不是在天然同二聚体SOD1的分子表面上的抗体。 此外，本发明包括在受试者中诊断阿尔茨海默病，帕金森病或肌萎缩性侧索硬化的方法。 此外，本发明提供了鉴定用于治疗或预防阿尔茨海默病，帕金森病或肌萎缩性侧索硬化的物质以及使用本发明的结合蛋白的试剂盒的方法。

公开(公告)号：WO2012004757A3

公开(公告)日：2012-06-28

申请号：PCT/IB2011053006

申请日：2011-07-06

Applicant: UNIV HEALTH NETWORK ,  INST NAT OPTIQUE ,  RINK ALEXANDRA ,  JAFFRAY DAVID ,  MERMUT OZZY ,  CARON SERGE ,  CROTEAU ANDRE ,  ROY-MOISAN FRANCOIS

Inventor： RINK ALEXANDRA ,  JAFFRAY DAVID ,  MERMUT OZZY ,  CARON SERGE ,  CROTEAU ANDRE ,  ROY-MOISAN FRANCOIS

IPC: G01T1/02

CPC classification number: G01T1/06 ,  G01T1/04 ,  G01T1/201 ,  Y10T29/49826

Abstract: A fiber optic dosimeter probe for sensing radiation dose including an optical fiber having a free end and a sensitive end, a window having a sensitive side and a rear side; a radiation sensitive layer between the sensitive end of the optical fiber and a sensitive side of the window, the radiation sensitive layer being made of a material having an optical property that changes with absorbed radiation dose, an amount of the material corresponding to a predetermined sensitivity to radiation; wherein the window and the optical fiber have a near water equivalent interaction with radiation and are MR compatible.

Abstract translation: 一种用于感测辐射剂量的光纤剂量计探针，包括具有自由端和敏感端的光纤，具有敏感侧和后侧的窗口; 在光纤的敏感端和窗口的敏感侧之间的辐射敏感层，辐射敏感层由具有随吸收辐射剂量变化的光学性质的材料制成，材料的量对应于预定灵敏度 辐射; 其中窗口和光纤与辐射具有近水当量的相互作用并且是MR兼容的。

公开(公告)号：WO2011123947A8

公开(公告)日：2011-12-22

申请号：PCT/CA2011000387

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK ,  CUMMING GRAHAM ,  PATEL NARENDA KUMAR B ,  FORREST BRYAN T ,  LIU YONG ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  EDWARDS LOUISE G ,  PAULS HEINZ W

Inventor： CUMMING GRAHAM ,  PATEL NARENDA KUMAR B ,  FORREST BRYAN T ,  LIU YONG ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  EDWARDS LOUISE G ,  PAULS HEINZ W

IPC: C07D403/04 ,  C07D231/56 ,  C07D413/14

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.

Abstract translation: 本发明涉及用于制备由结构式（A）表示的螺环丙基吲哚啉酮化合物的新型合成方法：（A）或其药学上可接受的盐。 还包括本文所述的合成中间体。

公开(公告)号：WO2011029190A1

公开(公告)日：2011-03-17

申请号：PCT/CA2010001409

申请日：2010-09-09

Applicant: ENGINEERING SERVICES INC ,  UNIV HEALTH NETWORK ,  GOLDENBERG ANDREW A ,  TRACHTENBERG JOHN ,  YANG YI ,  MA LIANG

Inventor： GOLDENBERG ANDREW A ,  TRACHTENBERG JOHN ,  YANG YI ,  MA LIANG

IPC: A61B19/00 ,  A61B5/055 ,  A61B8/00

CPC classification number: A61B5/055 ,  A61B8/0833 ,  A61B8/0841 ,  A61B8/12 ,  A61B8/4209 ,  A61B8/5238 ,  A61B90/11 ,  A61B2034/2059 ,  A61B2090/364 ,  A61B2090/374 ,  A61B2090/378 ,  A61N5/1007

Abstract: A medical device is for use in association with a medical image of the gland or organ having a known reference point. The medical device comprises a structural frame, a horizontal joint, a vertical joint, a pan join, a tilt joint a medical instrument assembly and a control system. The medical device is positioned at a predetermined location relative to the medical image reference point. Each of the horizontal joint, the vertical joint, the pan joint and the tilt joint have a position sensor and are operably connected to the frame. The medical instrument assembly is operably connected to a sensor and to the horizontal joint, the vertical joint, the pan joint and the tilt joint. The control system is operably connected to the other elements whereby the control system determines the position of a predetermined location on the medical instrument assembly relative to the structural frame.

Abstract translation: 医疗装置用于与具有已知参考点的腺体或器官的医学图像相关联。 医疗设备包括结构框架，水平接头，垂直接头，平底接头，医疗器械组件和控制系统的倾斜接头。 医疗设备被定位在相对于医学图像参考点的预定位置处。 水平关节，垂直关节，平底关节和倾斜关节中的每一个都具有位置传感器并且可操作地连接到框架。 医疗器械组件可操作地连接到传感器以及水平关节，垂直关节，平底关节和倾斜关节。 控制系统可操作地连接到其他元件，由此控制系统相对于结构框架确定医疗器械组件上的预定位置的位置。

公开(公告)号：WO2005039479A9

公开(公告)日：2007-03-29

申请号：PCT/CA2004001857

申请日：2004-10-22

Applicant: UNIV HEALTH NETWORK ,  BURCH SHANE ,  WILSON BRIAN C ,  BISLAND STUART K

Inventor： BURCH SHANE ,  WILSON BRIAN C ,  BISLAND STUART K

IPC: A61B17/86 ,  A61B18/22 ,  A61N5/06

CPC classification number: A61N5/062 ,  A61B17/864 ,  A61B18/22 ,  A61N5/0601

Abstract: Photodynamic therapy (PDT) is used in the case of bone. A photosensitizing drug is administered to a mammal. A bone insertion member is secured into bone. A fiber optic cable sheath extends from within the bone insertion member and is accessible. A fiber optic cable is inserted in the fiber optic cable sheath to deliver light to the bone. A locking member is then attached to the insertion member. Non-thermal light at a specific wavelength is then delivered to activate the drug. The insertion member and the fiber optic cable sheath may remain inside the mammal for further photodynamic therapy.

Abstract translation: 在骨骼的情况下使用光动力疗法（PDT）。 向哺乳动物施用光敏药物。 骨插入构件被固定到骨中。 光缆护套从骨插入构件内部延伸并且可接近。 将光纤电缆插入到光缆护套中以将光传送到骨头。 然后将锁定构件附接到插入构件。 然后递送特定波长的非热光以激活药物。 插入构件和光缆护套可以保留在哺乳动物内用于进一步的光动力学治疗。

公开(公告)号：WO2005039479A2

公开(公告)日：2005-05-06

申请号：PCT/CA2004001857

申请日：2004-10-22

Applicant: UNIV HEALTH NETWORK ,  BURCH SHANE ,  WILSON BRIAN C ,  BISLAND STUART K

Inventor： BURCH SHANE ,  WILSON BRIAN C ,  BISLAND STUART K

IPC: A61B17/86 ,  A61B18/22 ,  A61N5/06 ,  A61K

CPC classification number: A61N5/062 ,  A61B17/864 ,  A61B18/22 ,  A61N5/0601

Abstract: Photodynamic therapy (PDT) is used in the case of bone. A photosensitizing drug is administered to a mammal. A bone insertion member is secured into bone. A fiber optic cable sheath extends from within the bone insertion member and is accessible. A fiber optic cable is inserted in the fiber optic cable sheath to deliver light to the bone. A locking member is then attached to the insertion member. Non-thermal light at a specific wavelength is then delivered to activate the drug. The insertion member and the fiber optic cable sheath may remain inside the mammal for further photodynamic therapy.

Abstract translation: 光动力疗法（PDT）用于骨骼的情况。 将光敏药物给予哺乳动物。 骨插入构件被固定到骨中。 光纤电缆护套从骨插入构件内延伸并且可以接近。 将光纤电缆插入光纤电缆护套中以将光传送至骨骼。 然后将锁定构件附接到插入构件。 然后传递特定波长的非热量激发光以激活药物。 插入构件和光缆护套可以保留在哺乳动物体内用于进一步的光动力治疗。

公开(公告)号：WO03038062A3

公开(公告)日：2003-10-16

申请号：PCT/US0235240

申请日：2002-10-31

Applicant: US GOV HEALTH & HUMAN SERV ,  UNIV PENNSYLVANIA ,  UNIV HEALTH NETWORK ,  FOWLER DANIEL ,  JUNG UNSU ,  MEDIN JEFFREY A ,  GRESS RONALD E ,  ERDMANN ANDREAS ,  LEVINE BRUCE ,  JUNE CARL

Inventor： FOWLER DANIEL ,  JUNG UNSU ,  MEDIN JEFFREY A ,  GRESS RONALD E ,  ERDMANN ANDREAS ,  LEVINE BRUCE ,  JUNE CARL

IPC: A01K67/027 ,  A61K35/12 ,  A61K39/00 ,  C12N5/02 ,  C12N5/071 ,  C12N5/0783 ,  C12N5/00 ,  A01N63/00 ,  A61K35/26 ,  A61K35/28

CPC classification number: C12N5/0648 ,  A01K67/0271 ,  A61K39/001 ,  A61K2035/122 ,  A61K2035/124 ,  C12N5/0636 ,  C12N2500/32 ,  C12N2501/23 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2510/00 ,  C12N2799/021

Abstract: A method is provided for producing a population of CD8 Tc1 and/or Tc2 lymphocytes ex vivo. The method includes stimulating a population of T cells obtained from a subject by contacting the population with an anti-CD3 monoclonal antibody and an antibody that specifically binds to a T cell costimulatory molecule in the presence of a Tc1 or Tc2 supportive environment to form a stimulated population of T cells. The stimulated population of CD8 T cells is allowed to proliferate in a Tc1 or Tc2 supportive environment. Purified populations of Tc1 and Tc2 cells are disclosed herein, as are methods for their use.

Abstract translation: 提供了一种离体生成CD8 + Tc1和/或Tc2淋巴细胞群体的方法。 所述方法包括通过使所述群体与抗CD3单克隆抗体和在Tc1或Tc2支持环境存在下特异性结合T细胞共刺激分子的抗体接触以刺激从受试者获得的T细胞群以形成刺激 T细胞群。 使受刺激的CD8 + T细胞群在Tc1或Tc2支持环境中增殖。 本文公开了纯化的Tc1和Tc2细胞群，以及它们的使用方法。

公开(公告)号：WO0118037A3

公开(公告)日：2001-11-08

申请号：PCT/CA0001021

申请日：2000-09-07

Applicant: UNIV HEALTH NETWORK ,  BENCHIMOL SAMUEL ,  LIN YUNPING

Inventor： BENCHIMOL SAMUEL ,  LIN YUNPING

IPC: A61K38/00 ,  C07K14/47 ,  C12N15/12 ,  A01K67/027 ,  A61K31/70 ,  A61K39/395 ,  A61K48/00 ,  C07K16/18 ,  C12N15/11 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68

CPC classification number: C07K14/4747 ,  A01K2217/075 ,  A61K38/00

Abstract: The invention relates to nucleic acid molecules encoding a p53 induced protein with a death domain that can promote apoptosis; the proteins encoded by the nucleic acid molecules; and, uses of the proteins and nucleic acid molecules, especially in the treatment of cancer and dysplasia, autoimmune disease neurodegenerative disorders, or stroke.

Abstract translation: 本发明涉及编码具有可促进凋亡的死亡结构域的p53诱导的蛋白质的核酸分子; 由核酸分子编码的蛋白质; 以及蛋白质和核酸分子的用途，特别是在治疗癌症和发育异常，自身免疫性疾病，神经退行性疾病或中风中的用途。

公开(公告)号：WO0162668A2

公开(公告)日：2001-08-30

申请号：PCT/CA0100234

申请日：2001-02-26

Applicant: UNIV HEALTH NETWORK ,  LANGLER RICHARD FRANCIS ,  BAERLOCKER FELIX J ,  PENN LINDA Z

Inventor： LANGLER RICHARD FRANCIS ,  BAERLOCKER FELIX J ,  PENN LINDA Z

IPC: A61P31/04 ,  A01N41/10 ,  A01N41/12 ,  A61K31/10 ,  A61P31/10 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  C07C313/02 ,  C07C313/12 ,  C07C319/22 ,  C07C323/12 ,  C07C323/19 ,  C07C323/22 ,  C07C323/65 ,  C01B31/26

CPC classification number: C07C323/12 ,  C07C313/02 ,  C07C323/22 ,  C07C323/65

Abstract: This invention is directed to novel and known sulfur containing compounds and pharmaceutically acceptable salts thereof that have utility as antifungals and as antiproliferative agents against mammalian cells, in particular cancer cells and most particularly leukemia-derived cells. The invention provides a method for synthesizing certain of the sulfur containing compounds that is more efficient than previously known methods.

Abstract translation: 本发明涉及新颖且已知的含硫化合物及其药学上可接受的盐，其具有抗真菌剂的作用，并且作为抗哺乳动物细胞，特别是癌细胞，特别是白血病衍生细胞的抗增殖剂。 本发明提供了一种合成某些含硫化合物的方法，其比先前已知的方法更有效。